. 2022 Apr;76(4):841-849.

doi: 10.1016/j.jhep.2021.12.041. Epub 2022 Jan 20.

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Simon Pape¹, Romée J A L M Snijders¹, Tom J G Gevers², Oliver Chazouilleres³, George N Dalekos⁴, Gideon M Hirschfield⁵, Marco Lenzi⁶, Michael Trauner⁷, Michael P Manns⁸, John M Vierling⁹, Aldo J Montano-Loza¹⁰, Ansgar W Lohse¹¹, Christoph Schramm¹², Joost P H Drenth¹, Michael A Heneghan¹³; International Autoimmune Hepatitis Group (IAIHG) collaborators(‡)

Collaborators, Affiliations

Collaborators

International Autoimmune Hepatitis Group (IAIHG) collaborators(‡):
P Almasio, F Alvarez, R Andrade, C Arikan, D Assis, E Bardou-Jacquet, M Biewenga, E Cancado, N Cazzagon, O Chazouillères, G Colloredo, M Cuarterolo, G Dalekos, D Debray, M Robles-Díaz, J Drenth, J Dyson, C Efe, B Engel, S Ferri, R Fontana, N Gatselis, A Gerussi, E Halilbasic, N Halliday, M Heneghan, G Hirschfield, B van Hoek, M Hørby Jørgensen, G Indolfini, R Iorio, S Jeong, D Jones, D Kelly, N Kerkar, F Lacaille, C Lammert, B Leggett, M Lenzi, C Levy, R Liberal, A Lleo, A Lohse, S Ines Lopez, E de Martin, V McLin, G Mieli-Vergani, P Milkiewicz, N Mohan, L Muratori, G Nebbia, C van Nieuwkerk, Y Oo, A Ortega, A Páres, T Pop, D Pratt, T Purnak, G Ranucci, S Rushbrook, C Schramm, A Stättermayer, M Swain, A Tanaka, R Taubert, D Terrabuio, B Terziroli, M Trauner, P Valentino, F van den Brand, A Villamil, S Wahlin, H Ytting, K Zachou, M Zeniya

Affiliations

¹ Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
² Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht 6229HX, The Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
³ Hepatology Department, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, Saint-Antoine Hospital Assistance Publique-Hôpitaux de Paris, Paris, France; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
⁴ Department of Medicine and Research Laboratory of Internal Medicine, University of Thessaly Medical School, Larissa, Greece.
⁵ Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.
⁶ Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi, University of Bologna, Bologna, Italy.
⁷ Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
⁸ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
⁹ Departments of Medicine and Surgery, Baylor College of Medicine, Houston, TX, USA.
¹⁰ Division of Gastroenterology and Hepatology, University of Alberta Hospital, Edmonton, Canada.
¹¹ 1(st) Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
¹² 1(st) Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Martin Zeitz Centre for Rare Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
¹³ Institute of Liver Studies, King's College Hospital, London, United Kingdom; European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Electronic address: michael.heneghan@nhs.net.

PMID: 35066089
DOI: 10.1016/j.jhep.2021.12.041

Free article

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Simon Pape et al. J Hepatol. 2022 Apr.

Free article

. 2022 Apr;76(4):841-849.

doi: 10.1016/j.jhep.2021.12.041. Epub 2022 Jan 20.

Authors

Collaborators

International Autoimmune Hepatitis Group (IAIHG) collaborators(‡):
P Almasio, F Alvarez, R Andrade, C Arikan, D Assis, E Bardou-Jacquet, M Biewenga, E Cancado, N Cazzagon, O Chazouillères, G Colloredo, M Cuarterolo, G Dalekos, D Debray, M Robles-Díaz, J Drenth, J Dyson, C Efe, B Engel, S Ferri, R Fontana, N Gatselis, A Gerussi, E Halilbasic, N Halliday, M Heneghan, G Hirschfield, B van Hoek, M Hørby Jørgensen, G Indolfini, R Iorio, S Jeong, D Jones, D Kelly, N Kerkar, F Lacaille, C Lammert, B Leggett, M Lenzi, C Levy, R Liberal, A Lleo, A Lohse, S Ines Lopez, E de Martin, V McLin, G Mieli-Vergani, P Milkiewicz, N Mohan, L Muratori, G Nebbia, C van Nieuwkerk, Y Oo, A Ortega, A Páres, T Pop, D Pratt, T Purnak, G Ranucci, S Rushbrook, C Schramm, A Stättermayer, M Swain, A Tanaka, R Taubert, D Terrabuio, B Terziroli, M Trauner, P Valentino, F van den Brand, A Villamil, S Wahlin, H Ytting, K Zachou, M Zeniya

Affiliations

¹ Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
² Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht 6229HX, The Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
³ Hepatology Department, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, Saint-Antoine Hospital Assistance Publique-Hôpitaux de Paris, Paris, France; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
⁴ Department of Medicine and Research Laboratory of Internal Medicine, University of Thessaly Medical School, Larissa, Greece.
⁵ Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.
⁶ Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi, University of Bologna, Bologna, Italy.
⁷ Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
⁸ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
⁹ Departments of Medicine and Surgery, Baylor College of Medicine, Houston, TX, USA.
¹⁰ Division of Gastroenterology and Hepatology, University of Alberta Hospital, Edmonton, Canada.
¹¹ 1(st) Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
¹² 1(st) Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Martin Zeitz Centre for Rare Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
¹³ Institute of Liver Studies, King's College Hospital, London, United Kingdom; European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Electronic address: michael.heneghan@nhs.net.

PMID: 35066089
DOI: 10.1016/j.jhep.2021.12.041

Abstract

Background & aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment.

Methods: A systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis.

Results: The consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term 'complete biochemical response' defined as 'normalization of serum transaminases and IgG below the upper limit of normal' be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as '<50% decrease of serum transaminases within 4 weeks after initiation of treatment'. Remission is defined as liver histology with a Hepatitis Activity Index <4/18. Intolerance to treatment was agreed to stand for 'any adverse event possibly related to treatment leading to potential drug discontinuation'.

Conclusions: These definitions provide a simple and reproducible framework to define treatment response and non-response, irrespective of the therapeutic intervention. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable inter-study comparisons. Future prospective database studies are needed to validate these endpoints.

Lay summary: Consensus among international experts on response criteria and endpoints in autoimmune hepatitis is lacking. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable the comparison of results between clinical trials. Therefore, the International Autoimmune Hepatitis Group (IAIHG) herein presents a statement on 5 agreed response criteria and endpoints: complete biochemical response, insufficient response, non-response, remission, and intolerance to treatment, which can be used to guide future reporting.

Keywords: autoimmune hepatitis; complete biochemical response; endpoints; insufficient response; intolerance; non-response; remission.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest All authors report no potential conflicts that are relevant to the manuscript. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment in

2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: A too early endpoint?
Medas R, Liberal R, Cardoso H, Macedo G. Medas R, et al. J Hepatol. 2022 Nov;77(5):1461-1462. doi: 10.1016/j.jhep.2022.06.007. Epub 2022 Jun 16. J Hepatol. 2022. PMID: 35716845 No abstract available.
Rapid response predicts complete biochemical response and histological remission in autoimmune hepatitis.
Li Y, Xiao X, Miao Q, Ma X. Li Y, et al. J Hepatol. 2022 Nov;77(5):1463-1464. doi: 10.1016/j.jhep.2022.07.012. Epub 2022 Jul 20. J Hepatol. 2022. PMID: 35870704 No abstract available.
Reply to: "Correspondence on 'Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group'": Defining endpoints that guide treatment in autoimmune hepatitis.
Snijders RJALM, Gevers TJG, Heneghan MA, Drenth JPH. Snijders RJALM, et al. J Hepatol. 2022 Nov;77(5):1464-1466. doi: 10.1016/j.jhep.2022.07.025. Epub 2022 Aug 17. J Hepatol. 2022. PMID: 35985543 No abstract available.
2022 International autoimmune hepatitis group non-response criteria in autoimmune hepatitis: Quick vs. slow responders.
Engel B, Jaeckel E, Taubert R. Engel B, et al. J Hepatol. 2023 Mar;78(3):e113-e114. doi: 10.1016/j.jhep.2022.09.026. Epub 2022 Oct 13. J Hepatol. 2023. PMID: 36243178 No abstract available.
Reply to: "2022 international autoimmune hepatitis group non-response criteria in autoimmune hepatitis: Quick vs. slow responders".
Snijders RJALM, Gevers TJG, Drenth JPH. Snijders RJALM, et al. J Hepatol. 2023 Mar;78(3):e115. doi: 10.1016/j.jhep.2022.11.031. Epub 2022 Dec 16. J Hepatol. 2023. PMID: 36535600 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Collaborators

Affiliations

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Comment in

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical